CNS 2
1. Acute Pyogenic (Bacterial) Meningitis
Pathophysiology:
Pathogens: Common bacteria include Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae (mostly in children), and Group B Streptococcus (in neonates).
Entry: Bacteria enter the bloodstream through respiratory droplets, typically colonizing the nasopharynx, and then cross the blood-brain barrier to reach the meninges.
Immune response: Once in the subarachnoid space, bacteria trigger a robust immune response, with neutrophils, cytokines, and inflammatory mediators causing a purulent inflammation that raises intracranial pressure and can cause brain edema.
Complications: Edema and inflammation can lead to herniation, hydrocephalus, and vasculitis, which can disrupt blood flow and damage brain tissue.
Clinical Features:
Classic symptoms are fever, severe headache, neck stiffness, and photophobia.
Neurological signs: Confusion, seizures, and coma in severe cases.
Meningeal signs: Positive Kernig’s (pain with hip flexion) and Brudzinski’s signs (neck flexion induces hip/knee flexion) can be seen but vary in reliability.
Rash: N. meningitidis may cause a petechial rash due to endotoxin release.
CSF Findings:
Turbid or purulent appearance due to high neutrophil count.
Increased protein levels due to inflammation.
Markedly decreased glucose as bacteria consume glucose.
Positive Gram stain or culture confirms bacterial type.
Treatment:
Immediate empiric antibiotics (e.g., ceftriaxone, vancomycin) to cover likely pathogens, adjusted based on CSF culture.
Corticosteroids like dexamethasone may reduce inflammation, helping to prevent complications such as hearing loss.
2. Acute Aseptic (Viral) Meningitis
Pathophysiology:
Pathogens: Primarily caused by enteroviruses, HSV, mumps, and HIV.
Transmission: Viruses spread through blood to the CNS or directly enter via nerve routes (e.g., HSV along cranial nerves).
Immune response: Viral invasion causes a milder, non-purulent lymphocytic inflammation without severe neutrophilic reaction.
Minimal damage to the blood-brain barrier compared to bacterial infections.
Clinical Features:
Fever, headache, and photophobia similar to bacterial meningitis but usually milder.
Neck stiffness is often present, but patients remain more alert.
Atypical symptoms: Some viruses can cause skin rashes or mild respiratory symptoms.
CSF Findings:
Clear appearance; lymphocytic predominance (mainly lymphocytes).
Slightly elevated protein, but glucose levels remain normal or mildly reduced.
PCR can identify specific viral DNA or RNA for diagnosis.
Treatment:
Primarily supportive care (fluids, rest, pain management).
Antivirals: Acyclovir for HSV, as early treatment can prevent serious outcomes like encephalitis.
Most viral infections resolve on their own without complications.
3. Acute Focal Suppurative Infections (e.g., Brain Abscess)
Pathophysiology:
Pathogens: Often polymicrobial, including Staphylococcus aureus, streptococci, and anaerobes.
Routes of infection: Bacteria can reach the brain from contiguous infections (sinusitis, mastoiditis) or via hematogenous spread (endocarditis).
Formation: Bacteria form localized abscesses surrounded by a fibrous capsule.
Complications: Edema around the abscess causes increased intracranial pressure and may lead to herniation.
Clinical Features:
Headache, focal neurological deficits (e.g., weakness, speech difficulty), seizures, and fever.
Symptoms vary depending on abscess location; frontal lobe abscesses may cause personality changes, while temporal lobe abscesses can affect speech.
Increased intracranial pressure signs: Vomiting, papilledema.
CSF Findings:
Elevated intracranial pressure, with mildly elevated white cells.
Protein increased, but glucose is typically normal since infection is localized.
Imaging (CT/MRI) is the primary diagnostic tool, showing ring-enhancing lesions.
Treatment:
Surgical drainage or aspiration.
Targeted antibiotic therapy based on culture results; broad-spectrum antibiotics initially.
Corticosteroids may be used to reduce surrounding edema.
4. Chronic Bacterial Meningoencephalitis (e.g., Tuberculous Meningitis)
Pathophysiology:
Pathogens: Mycobacterium tuberculosis commonly spreads to CNS in immunocompromised patients.
Spread: Hematogenous dissemination from primary infection sites (often the lungs).
Response: Granulomatous inflammation forms tuberculomas, with macrophages, lymphocytes, and multinucleated giant cells.
Complications: Basal meningeal involvement can block CSF flow, causing hydrocephalus.
Clinical Features:
Gradual onset: Headache, low-grade fever, night sweats, and weight loss.
Neurologic deficits: Cranial nerve palsies, visual disturbances.
Subacute progression, with gradual decline in mental function and possible seizures.
CSF Findings:
Lymphocytic pleocytosis, elevated protein, and very low glucose.
Acid-fast bacilli can be detected with staining or culture; PCR for TB DNA is often diagnostic.
Treatment:
Prolonged anti-TB therapy (isoniazid, rifampin, pyrazinamide, ethambutol).
Corticosteroids to reduce inflammation and prevent complications like hydrocephalus.
5. Viral Meningoencephalitis
Pathophysiology:
Pathogens: Caused by HSV, West Nile virus, Rabies, etc.
Mechanism: Virus directly infects neurons or glial cells, causing cell death and inflammation.
Inflammation spreads across the brain parenchyma, damaging neurons, especially in the temporal lobe with HSV.
Clinical Features:
Fever, confusion, altered consciousness, and focal neurological signs (e.g., hemiparesis).
Seizures, especially in HSV infections.
Certain viruses can have specific signs, such as hydrophobia in rabies.
CSF Findings:
Lymphocytic pleocytosis, elevated protein, normal glucose.
PCR for specific viral identification (e.g., HSV DNA).
Treatment:
Supportive care; antiviral therapy for HSV (acyclovir).
Severe cases may require intensive care for supportive respiratory management.
6. Fungal Meningoencephalitis
Pathophysiology:
Pathogens: Cryptococcus neoformans, Aspergillus, Candida.
Predisposition: Immunocompromised states (e.g., HIV/AIDS).
Invasion: Fungi form granulomas and abscesses; cryptococcal infections may form gelatinous cysts.
Clinical Features:
Subacute symptoms: Chronic headache, mental status change, mild fever.
Immune-compromised symptoms: Rapid progression, neurologic decline, seizures.
CSF Findings:
Lymphocytic pleocytosis, elevated protein, decreased glucose.
Positive fungal culture or antigen testing (e.g., cryptococcal antigen).
Treatment:
Antifungal agents (e.g., amphotericin B with flucytosine for Cryptococcus).
Long-term antifungal therapy may be necessary to prevent recurrence
Prion Diseases Overview
What Are Prion Diseases? Prion diseases, or transmissible spongiform encephalopathies (TSEs), are a group of rare, progressive, and invariably fatal neurodegenerative diseases caused by misfolded prion proteins (PrP). These diseases include Creutzfeldt-Jakob disease (CJD), variant CJD (vCJD), Gerstmann-Sträussler-Scheinker syndrome (GSS), and fatal familial insomnia (FFI).
1. Pathophysiology
Causative Agent: Prion diseases are caused by a misfolded form of the prion protein, known as PrP^Sc. This abnormal protein induces normal cellular prion proteins (PrP^C) to misfold into the same abnormal structure. Unlike other infectious agents, prions contain no DNA or RNA.
Mechanism of Spread: PrP^Sc propagates by inducing the misfolding of PrP^C in neurons, leading to the accumulation of prions in brain tissue. These aggregates are resistant to normal cellular degradation processes.
Cellular Damage: Accumulated PrP^Sc disrupts neuronal function, leading to cell death. The brain undergoes spongiform degeneration, where neurons die, leaving small vacuoles, giving brain tissue a “spongy” appearance.
Genetic vs. Acquired Forms:
Genetic Forms: Some prion diseases have a genetic basis, such as FFI and some forms of CJD, due to mutations in the PRNP gene.
Acquired Forms: Prions can also be acquired through contaminated surgical instruments, infected tissue transplants, or consumption of prion-infected meat (as seen in vCJD linked to Bovine Spongiform Encephalopathy, or “mad cow disease”).
2. Clinical Features
The clinical presentation varies between types of prion diseases but generally includes the following:
Rapidly Progressive Dementia: Memory loss, cognitive decline, personality changes, and psychiatric symptoms.
Myoclonus: Sudden, involuntary muscle jerks are a hallmark feature, particularly in CJD.
Cerebellar Dysfunction: Gait ataxia, dysarthria, and poor coordination.
Visual Disturbances: May include blurred vision, hallucinations, or cortical blindness.
Sleep Disorders: Particularly in FFI, insomnia becomes progressively severe and leads to autonomic dysfunction (e.g., sweating, fever).
Disease-Specific Signs:
CJD: Rapid cognitive decline with myoclonus and cerebellar symptoms.
vCJD: Behavioral changes and sensory disturbances with a slower progression compared to sporadic CJD.
FFI: Predominantly sleep disturbances with autonomic instability, such as fever, tachycardia, and sweating.
GSS: Progressive ataxia followed by dementia; symptoms often begin in mid-life.
3. CSF Findings
CSF examination can help support the diagnosis of prion diseases, although definitive diagnosis typically requires brain biopsy or autopsy.
Protein 14-3-3: This neuronal injury marker is elevated in sporadic CJD, though it’s not specific.
Tau Protein: Often elevated in CJD.
RT-QuIC Assay: The real-time quaking-induced conversion assay detects prion proteins in CSF with high sensitivity and specificity for CJD.
Non-Specific Findings: Mild elevation in CSF protein may be present, but white cell count and glucose levels are typically normal.
4. Treatment
Currently, no cure or effective treatment exists for prion diseases. Management focuses on symptomatic relief and supportive care.
Symptomatic Treatment: This includes medications to manage myoclonus (e.g., clonazepam, valproate) and antipsychotics for psychiatric symptoms.
Palliative Care: Emphasis on maintaining patient comfort, as disease progression is rapid and terminal.
Experimental Approaches: Ongoing research is exploring drugs that may inhibit PrP^Sc aggregation or propagation, though none are yet proven effective in clinical trials.
5. Diagnostic Imaging and Other Tests
MRI Findings: Brain MRI may show increased signal intensity in the basal ganglia, thalamus, and cortex on diffusion-weighted imaging (DWI), often in CJD.
Electroencephalography (EEG): Typical periodic sharp wave complexes (PSWC) on EEG are found in sporadic CJD.
Summary of Prion Diseases
Disease TypeTypical FeaturesPathologyUnique CSF FindingsOther Key Diagnostics | ||||
CJD | Rapid dementia, myoclonus, ataxia | Spongiform changes, PrP^Sc deposits | 14-3-3 protein, elevated tau | PSWC on EEG, basal ganglia changes |
vCJD | Psychiatric symptoms, sensory disturbances | PrP plaques with florid amyloid | Positive RT-QuIC | Bilateral thalamic hyperintensity |
FFI | Insomnia, autonomic instability | Thalamic gliosis, PrP^Sc in thalamus | Usually unremarkable | MRI may show thalamic atrophy |
GSS | Ataxia, cognitive decline, often familial | PrP amyloid plaques | RT-QuIC positive in some cases | Genetic testing for PRNP mutation |
Prion diseases remain a significant challenge in neurology due to their complex mechanisms, rapid progression, and lack of effective treatments. Further research aims to understand the exact pathogenesis and develop treatments that can halt or slow prion propagation.